These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 19014200)

  • 1. Does 'NICE blight' exist, and if so, why?
    Haycox A
    Pharmacoeconomics; 2008; 26(12):987-9. PubMed ID: 19014200
    [No Abstract]   [Full Text] [Related]  

  • 2. Report blames NICE for hastening decline of UK biotech.
    Moran N
    Nat Biotechnol; 2009 Mar; 27(3):215-7. PubMed ID: 19270658
    [No Abstract]   [Full Text] [Related]  

  • 3. Single technology appraisals by NICE: are they delivering faster guidance to the NHS?
    Barham L
    Pharmacoeconomics; 2008; 26(12):1037-43. PubMed ID: 19014204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of NICE technology appraisal in NHS rationing.
    Walker S; Palmer S; Sculpher M
    Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NICE is dead; long live NICE.
    Chinthapalli K
    BMJ; 2013 Apr; 346():f2546. PubMed ID: 23615594
    [No Abstract]   [Full Text] [Related]  

  • 6. On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales.
    Birch S; Gafni A
    Health Econ; 2002 Apr; 11(3):185-91. PubMed ID: 11921316
    [No Abstract]   [Full Text] [Related]  

  • 7. Differences in cancer drug assessment between Spain and the United Kingdom.
    Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
    Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 10 years of NICE: still growing and still controversial.
    Littlejohns P; Garner S; Doyle N; Macbeth F; Barnett D; Longson C
    Lancet Oncol; 2009 Apr; 10(4):417-24. PubMed ID: 19341973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health technology assessment in Canada: diversity and evolution.
    Hailey DM
    Med J Aust; 2007 Sep; 187(5):286-8. PubMed ID: 17767434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nice challenge for health economics.
    Hutton J; Maynard A
    Health Econ; 2000 Mar; 9(2):89-93. PubMed ID: 10721011
    [No Abstract]   [Full Text] [Related]  

  • 11. The Australian government's review of positron emission tomography: evidence-based policy decision-making in action.
    Lenzo NP
    Med J Aust; 2004 Nov; 181(9):516-7; author reply 517-8. PubMed ID: 15516203
    [No Abstract]   [Full Text] [Related]  

  • 12. The efficiency frontier approach to economic evaluation: will it help German policy making?
    Brouwer WB; Rutten FF
    Health Econ; 2010 Oct; 19(10):1128-31. PubMed ID: 20641141
    [No Abstract]   [Full Text] [Related]  

  • 13. A furore too far: the widespread disquiet undermining NICE.
    Carlisle D
    Health Serv J; 2006 Jun; 116(6011):14-5. PubMed ID: 16827515
    [No Abstract]   [Full Text] [Related]  

  • 14. Current technology assessment programs/procedures.
    McDonough R
    J Laparoendosc Surg; 1993 Aug; 3(4):395-7. PubMed ID: 8268513
    [No Abstract]   [Full Text] [Related]  

  • 15. IQWiG methods--a response to two critiques.
    Caro JJ; Nord E; Siebert U; McGuire A; McGregor M; Henry D; de Pouvourville G; Atella V; Kolominsky-Rabas P
    Health Econ; 2010 Oct; 19(10):1137-8. PubMed ID: 20842681
    [No Abstract]   [Full Text] [Related]  

  • 16. Some essential clarifications: IQWiG comments on two critiques of the efficiency frontier approach.
    Dintsios CM; Gerber A
    Health Econ; 2010 Oct; 19(10):1139-41. PubMed ID: 20842682
    [No Abstract]   [Full Text] [Related]  

  • 17. Sins of omission and obfuscation: IQWIG's guidelines on economic evaluation methods.
    Sculpher M; Claxton K
    Health Econ; 2010 Oct; 19(10):1132-6. PubMed ID: 20662107
    [No Abstract]   [Full Text] [Related]  

  • 18. NICE methodological guidelines and decision making in the National Health Service in England and Wales.
    Gafni A; Birch S; ;
    Pharmacoeconomics; 2003; 21(3):149-57. PubMed ID: 12558466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The failings of NICE. Reply from chairman of NICE.
    Rawlins MD
    BMJ; 2001 Feb; 322(7284):489. PubMed ID: 11222437
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
    Chen G; Peirce V; Marsh W
    Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.